Home › Funds › RA CAPITAL MANAGEMENT, L.P. › ASND
RA CAPITAL MANAGEMENT, L.P. position in ASND
ASCENDIS PHARMA A/S · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 10,281,496 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$2.74B, representing 23.83% of its reported portfolio and ranking #1 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed ASND holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s ASND position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in ASND in Q3 2023 at 10,719,555 shares (US$1.00B). The position peaked in Q2 2026 at 10,281,496 shares, worth US$2.74B. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 10,281,496 shares valued at US$2.74B.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 10.72M | $1.00B | New |
| Q4 2023 | 10.11M | $1.27B | Reduce |
| Q1 2024 | 10.11M | $1.53B | Hold |
| Q2 2024 | 10.11M | $1.38B | Hold |
| Q3 2024 | 9.71M | $1.45B | Reduce |
| Q4 2024 | 10.11M | $1.39B | Add |
| Q1 2025 | 10.28M | $1.60B | Add |
| Q2 2025 | 10.28M | $1.77B | Hold |
| Q3 2025 | 10.28M | $2.04B | Hold |
| Q4 2025 | 10.28M | $2.19B | Hold |
| Q1 2026 | 10.28M | $2.35B | Hold |
| Q2 2026 | 10.28M | $2.74B | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B), WESTFIELD CAPITAL MANAGEMENT CO LP (US$1.28B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M sh · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 4.80M sh · $1.28B · Q2 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.63M sh · $702.55M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K sh · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K sh · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
- Spyglass Capital Management LLC 215.40K sh · $57.45M · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held ASND?
RA CAPITAL MANAGEMENT, L.P. has disclosed ASND holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in ASND?
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 10.28M shares of ASND (ASCENDIS PHARMA A/S), valued at $2.74B, representing 23.83% of its reported portfolio and ranking #1.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling ASND?
In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in ASND. The position peaked in Q2 2026 at 10.28M shares.
Which other funds hold ASND?
Other major institutional holders of ASND include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, WESTFIELD CAPITAL MANAGEMENT CO LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.